Biotest Pharmaceuticals researches and manufactures biotherapeutic products with a specialization in immunology and liver transplant therapy. Biotest Pharmaceuticals is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and development of therapies to prevent re-infection of transplanted livers.

Biotest Pharmaceuticals was formed in 2007 as part of the acquisition of Nabi Biopharmaceuticals’ Biologics business unit which includes its plasmapheresis centers across the United States by Biotest AG. We employ more than 600 people in the US. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins therapies and diagnostics that employs approximately 1,850 people worldwide.

The information contained on this website is not intended to be a substitute for the advice of a health care professional, or a recommendation for any particular treatment plan. Medical information changes rapidly and it is important that consumers rely on the advice of a health care professional to employ good clinical judgment for the specific conditions of individual patients.